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Abstract
The repair process of damaged tissue involves the coordinated activities of several cell types in response to local
and systemic signals. Following acute tissue injury, infiltrating inflammatory cells and resident stem cells orchestrate
their activities to restore tissue homeostasis. However, during chronic tissue damage, such as in muscular
dystrophies, the inflammatory-cell infiltration and fibroblast activation persists, while the reparative capacity of stem
cells (satellite cells) is attenuated. Abnormal dystrophic muscle repair and its end stage, fibrosis, represent the final
common pathway of virtually all chronic neurodegenerative muscular diseases. As our understanding of the
pathogenesis of muscle fibrosis has progressed, it has become evident that the muscle provides a useful model for
the regulation of tissue repair by the local microenvironment, showing interplay among muscle-specific stem cells,
inflammatory cells, fibroblasts and extracellular matrix components of the mammalian wound-healing response.
This article reviews the emerging findings of the mechanisms that underlie normal versus aberrant muscle-tissue
repair.
Introduction
Pathophysiologic fibrosis, which is essentially an exces-
sive accumulation of extracellular matrix (ECM) compo-
nents, particularly collagen, is the end result of a
cascade of events proceeding from tissue injury via
inflammation, and resulting in permanent scar forma-
tion. Fibrosis can impair tissue function and cause
chronic diseases in a large variety of vital organs and tis-
sues, including bone marrow (BM). Despite the diverse
range of tissues susceptible to fibrosis, all fibrotic reac-
tions share common cellular and molecular mechanisms,
such as cell and tissue degeneration, leukocyte infiltra-
tion, persistent inflammation of the tissue, and prolifera-
tion of cells with a fibroblast-like phenotype. The
interplay and imbalance of different cell types sustains
the production of numerous growth factors, proteolytic
enzymes, angiogenic factors and fibrogenic cytokines,
which together perturb the microenvironment of the
damaged tissue, and stimulate the deposition of connec-
tive-tissue elements that progressively remodel, destroy
and replace the normal tissue architecture. However,
despite many common elements, there are also impor-
tant differences between distinct tissue systems, and the
identity of some cellular and soluble factors initiating
and contributing to fibrogenic pathways are still
unknown. Thus, improving our understanding of the
mechanisms, cell types and factors involved in this pro-
cess is crucial to develop treatment strategies for these
diseases.
The muscle tissue microenvironment controls
normal repair versus fibrosis development
Muscular dystrophies
In skeletal muscle, fibrosis is most often associated with
the muscular dystrophies, a clinically and molecularly
heterogeneous group of diseases. Phenotypically, these
diseases are characterized by inflammation of the muscle
tissue and skeletal-muscle wasting, which compromises
patient mobility so that affected people become confined
to a wheelchair. In the most severe cases, such as Duch-
enne muscular dystrophy (DMD, caused by the lack of
the dystrophin protein), muscle loss and fibrosis also
cause premature death through respiratory and cardiac
failure [1]. In many dystrophies, including DMD, the
mutation affects proteins that form a link between the
cytoskeleton and the basal lamina, generally resulting in
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any medium, provided the original work is properly cited.the disassembly of whole protein complexes. As a result,
the sarcolemma becomes fragile, especially during
intense contractile activity. In turn, there is focal or dif-
fuse damage to the fiber and increased entry of calcium,
although the underlying molecular mechanisms for
these effects have not yet been elucidated in detail [2].
Several parallels can also be made between the muscular
dystrophies and the idiopathic inflammatory myopathies
(IIMs), which share common phenotypic features such
as inflammation and muscle weakness, although the
underlying causes are different.
In normal muscle repair after acute injury, such as in
experimental animals and in humans after sports inju-
ries, damaged or dead fibers are first removed by inflam-
matory cells, and they are then repaired or replaced by
tissue-resident muscle stem cells known as satellite cells
[3]. However, in chronic human diseases such as DMD
and many other dystrophies, newly generated fibers are
also prone to degeneration because they retain the
underlying molecular defect, producing constant cycles
of fiber degeneration associated with chronic inflamma-
tion (Figure 1) [4]. Until a few years ago, satellite cells
were the only known post-natal regenerative cells with
myogenic potential. In DMD, this satellite-cell popula-
tion is either exhausted over time or it loses the capacity
to mediate repair, and the muscle tissue is progressively
replaced by adipose and fibrotic tissue. Fibrosis and loss
of muscle tissue in dystrophies not only reduces motile
and contractile functions, but also diminishes the
amount of target tissue available for therapeutic
Figure 1 Extracellular matrix (ECM) deposition in acute and chronic muscle regeneration. Acute injury to healthy muscle produces rapid
and controlled inflammation that removes dead and damaged myofibers, and promotes replacement of the injured muscle. However, in
conditions of chronic injury, as occurs in the muscular dystrophies, chronic inflammatory events result in the excessive accumulation of ECM
components, which inhibit myogenic repair and lead to muscle being replaced by fibrotic/scar tissue. (Top) Tibialis anterior muscles of mice
were injected with cardiotoxin and samples were taken at different stages of the regeneration process. A representative sample showing the
inflammatory phase, characterized by a transient increase in collagen deposition, and subsequently the resolving phase of healing, with
progressive recovery of the normal tissue morphology (hematoxylin and eosin). (Bottom) Evolution of the morphological changes seen in the
diaphragm of mdx dystrophic mice with disease progression, leading to heterogeneity in fiber size and increased collagen deposition between
the altered myofibers. Bars = 50 μm.
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[5]. Currently there is no effective therapy for DMD
despite continuing efforts. The only relatively effective
pharmacotherapy for DMD involves corticosteroid
administration, which prolongs muscle strength and
walking capacity in the early years, but eventually leads
to undesirable secondary effects [6]. Furthermore, there
is also no effective clinical treatment to combat or
attenuate fibrosis in patients with DMD. For these rea-
sons, recent studies using the mdx mouse model of
DMD have focused more attention on the cellular and
molecular mechanisms underlying fibrosis associated
with dystrophin deficiency. Importantly, these studies
have tested several pharmacological agents that target
muscle fibrosis, and the results strongly suggest that
combating the development of fibrosis could ameliorate
DMD progression and increase the success of new cell-
and gene-based therapies.
Aging muscle
As well as the muscular dystrophies, aging is associated
with loss of skeletal-muscle mass and function with con-
comitant fibrosis and ECM deposition. Age-associated
muscle loss (sarcopenia) causes and/or exacerbates age-
related health problems. Therefore, understanding the
processes involved is important not only for unraveling
the mechanisms of fibrosis, but also for improving qual-
ity of life and healthcare for the older person. Sarcope-
nia seems to occur by mechanisms that partly are
unique to it, and partly are common to other forms of
atrophy. Some of these may involve changes in soluble
effectors, such as altered hormone status, inflammatory
factors, and altered caloric and protein intake, perhaps
triggered by modifications or decline in the central and
peripheral nervous systems. The net consequence of
these alterations firstly involves progressive atrophy and
loss of individual muscle fibers, associated with conco-
mitant loss of motor units [7]. In addition, there is infil-
tration of fat and other non-contractile material, which
causes a reduction in muscle ‘quality’ [8]. At the ultra-
structural level, aging has also been associated with
myofibril disarrangements in a dystrophic animal model,
and drops in force without alterations in motor protein
function as measured by in vitro motility assays [9].
Additional factors associated with DMD and age-asso-
ciated fibrosis are discussed in further detail below.
Normal skeletal-muscle repair
In nature, survival of an organism can often depend on
the ability to rapidly repair damage to muscle from
mechanical trauma, exposure to toxins or infections.
This rapid resolution of tissue injury requires a sequen-
tial and well-orchestrated series of events. Perturbation
of any of these stages can result in unsuccessful muscle
regeneration, typically characterized by persistent degen-
eration of myofibers, inflammation and fibrosis [10-12].
The key events leading to normal and defective/fibrotic
muscle repair are shown in Figure 2 and 3, and detailed
below.
Immediately after skeletal-muscle injury, cytokines and
growth factors are released from both the injured blood
vessels and from infiltrating inflammatory cells [13,14].
These factors stimulate the migration of the inflamma-
tory cells to and at the site of injury, and mediate prolif-
eration and cell survival. Invading inflammatory cells are
also responsible for phagocytosing any cell debris. The
specific influence of many damage signals, growth fac-
tors and inflammatory molecules on satellite cells
remains unclear [14], but the next crucial stage of repair
is the formation of new muscle fibers by these cells.
This process begins with their activation, because satel-
lite cells normally lie in a quiescent state beneath the
basal lamina of muscle fibers, followed by their extensive
proliferation. Some cells undergo self-renewal to replen-
ish the satellite-cell pool, but most become committed
and subsequently differentiate. These later myoblasts
fuse either to themselves or to the damaged myofibers
to replace the lost muscle.
In addition to inflammatory and satellite cells, efficient
muscle repair also requires the migration and prolifera-
tion of fibroblasts, in order to produce new temporary
ECM components, such as collagen types I and III,
fibronectin, elastin, proteoglycans, and laminin. These
elements serve to stabilize the tissue, and they act as a
scaffold for the new fibers. Moreover, the satellite cells
also utilize the basement membranes of pre-existing
necrotic fibers to ensure the myofiber maintains a simi-
lar position. Basement membranes and temporary ECM
components are also crucial for guiding the formation
of neuromuscular junctions (NMJs) [15]. The formation
and degradation of the ECM is mediated by the expres-
sion of proteases and their specific inhibitors during tis-
sue repair. ECM degradation also leads to the
generation of protein fragments that mediate important
biological activities required to facilitate normal tissue
repair [16]. Finally, in addition to ECM remodeling,
angiogenesis facilitates the development of a new vascu-
lar network at the site of injury, while newly formed
muscle fibers undergo growth and maturation.
Inflammation in efficient muscle repair and fibrosis
The first event after muscle damage is the invasion of the
injury site by inflammatory cells. There is now a wealth
of evidence to suggest that the nature, duration and
intensity of the inflammatory response after muscle
damage and regeneration can crucially influence the
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Figure 2 Chronic inflammation leads to fibrosis in skeletal-muscle repair. Resident and extravasating peripheral macrophages play an
important role in the early stages of muscle repair after acute injury, with pro-inflammatory (M1) macrophages first acting to clear the damage,
and anti-inflammatory (M2c) macrophages and alternatively activated macrophages (M2a), implicated in the subsequent resumption of
inflammation, extracellular matrix (ECM) deposition and tissue repair. M2c and M2a macrophages release anti-inflammatory cytokines and pro-
fibrotic molecules such as transforming growth factor (TGF)-b, which in turn activate fibroblasts in a regulated manner to produce ECM
components and ECM-remodeling factors, including autocrine production of TGFb, collagen, fibronectin, serine proteases (such as uPA/plasmin),
and metalloproteinases (MMPs) and their inhibitors (TIMPs). However, during chronic tissue damage, as in muscular dystrophies, the increased
and persistent presence of macrophages modify the intensity, duration and interactions of these released factors, leading to excessive ECM
accumulation and replacement of muscle with fibrotic tissue.
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[12,14,17,18]. For example, interfering with the transient
inflammatory response after acute injury may negatively
affect the phagocytosis of dead and damaged fibers,
thereby impeding the formation of new tissue. By
contrast, modulating the chronically high levels of inflam-
mation in dystrophic muscle can be beneficial in reducing
both muscle degeneration and fibrosis, while simulta-
neously promoting regeneration [19].
These results highlight two key notions: firstly, that
some form of inflammatory response is necessary to
repair damaged tissues effectively; and secondly, that
chronic inflammatory responses drive unrestrained
wound healing and fibrosis.
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Figure 3 Inflammatory control of skeletal-muscle regeneration. Replacement of damaged muscle fibers is dependent on satellite cells,
resident stem cells that are normally quiescent, and are located under the basal lamina of muscle fibers. Tissue damage leads to their activation,
proliferation, differentiation and fusion to form new myofibers. However, their capacity to mediate repair is modified by the extent and type of
injury, and consequently by their interaction with various cellular and soluble mediators, most importantly with infiltrating macrophages. The
proposed paracrine interaction between macrophages and satellite cells is as follows. During the timely, regulated process of regeneration after
acute injury (left), pro-inflammatory cytokines released from M1-macrophages may promote satellite-cell proliferation, whereas cytokines released
by anti-inflammatory (M2c) and alternatively activated (M2a) macrophages, respectively, may favor their differentiation and fusion. In particular,
interleukin (IL)-4 was shown to regulate fusion of myoblasts in vitro and in vivo [129]. It could be expected that, during chronic damage (right),
such as in muscular dystrophies, the increased and persistent presence of the distinct macrophage cell types could modify the relative levels
and kinetics of these cytokines, resulting in altered satellite-cell functions and aberrant regeneration, with progressive development of fibrosis
and fat accumulation, ultimately leading to non-functional muscle tissue.
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The earliest phases of tissue repair are generally charac-
terized by local activation of the innate immune system,
even though the original immunogenic stimuli are not
always known (see below) [20]. Macrophages have a pro-
m i n e n tr o l ei nt h ei n n a t ei m m u n er e s p o n s et oi n f e c t i o n
and/or tissue injury, because of their ability to phagocy-
tose particles such as bacteria or cellular debris, and to
secrete pro-inflammatory cytokines [13]. Recent studies
have shown that resident macrophages in the muscle epi-
mysium/perimysium orchestrate the innate immune
response to injury, which is linked to adaptive immunity
through inflammatory dendritic cells [21]. In addition to
tissue-resident macrophages, invasion of the site of
damage involves both polymorphonuclear leukocytes (for
example, neutrophils) and blood-derived monocytes,
which also differentiate into macrophages [17]. In some
tissues, other inflammatory-cell types such as mast cells
and T cells also play a key role in repair and fibrogenesis,
although to date there are only limited studies into the
role of these cells in muscle repair and DMD [22].
The principal inflammatory cells present in injured
muscle are monocytes and macrophages [17]. In regen-
erating and dystrophic muscle, these serve to clear myo-
fiber debris and in part, they modulate regeneration by
secreting cytokines. An important development in our
understanding of muscle repair and fibrosis was the
demonstration that a heterogeneous population of
macrophages exists in regenerating muscle after injury,
exhibiting opposing activities (either pro-inflammatory
or anti-inflammatory) and different kinetics [23]. A
nomenclature for polarized macrophages has been pro-
posed [24,25] and they are now referred to as classically
and alternatively activated macrophages, or M1 and M2
macrophages, respectively (Figure 2, Figure 3).
Classically activated (M1) or pro-inflammatory macro-
phages, arise from exposure to the T-helper (Th)1 cyto-
kines interferon-(IFN)g and tumor necrosis factor
(TNF)-a, in addition to lipopolysaccharide (LPS) or
endotoxin [24-26]. M1 macrophages play a key role in
acute inflammatory processes, and they are therefore
considered to be the prototypic macrophage. They are
found during the early stages after muscle damage in
association with recruited monocytes, and they partici-
pate in the processing and presentation of antigens, and
in the phagocytic removal of necrotic material. M1
macrophages also produce high levels of pro-inflamma-
tory cytokines, such as TNFa and interleukin (IL)-1b
a n dI L - 1 2 .I na d d i t i o n ,t h e yc a nb ei n d u c e dt oe x p r e s s
nitric oxide synthase (iNOS; also known as NOS2),
which is required to efficiently metabolize L-arginine to
generate the large amounts of NO involved in killing
intracellular pathogens.
The population of M2 macrophages is more complex
than that of the M1 macrophages, and it is currently
divided into distinct subtypes, reflecting different func-
tional specializations. M2a macrophages or strictly
speaking, alternatively activated macrophages, are acti-
vated by the Th2 cytokines IL-4 and IL-13, and are
most commonly associated with tissue repair, wound
healing and fibrosis. M2c macrophages are considered
to be anti-inflammatory, because they play a key role in
deactivating the M1 phenotype and they promote the
proliferation of non-myeloid cells. M2c macrophages
release anti-inflammatory cytokines, and they are primed
by IL-10. Thus, classically activated M1 macrophages
are usually found in the early stages after muscle injury,
closely followed by M2c macrophages [23]. M2a macro-
phages are abundant in advanced stages of the tissue-
repair process [12], and have been found in fibrotic
muscle of mdx mice [27,28] (Figure 4C).
From muscle injury to the chronic inflammatory response
and pathological muscle fibrosis
Alterations in the intensity or duration of macrophage
responses can have profound effects on muscle regen-
eration and fibrosis. One example of this was the dele-
tion of IL-10 in mdx mice, which increased muscle
damage and reduced muscle strength, due to an imbal-
ance between M1 and M2 macrophages [29]. Similarly,
p e r s i s t e n c eo fM 1m a c r o p h ages has been proposed to
have pathological consequences in chronic inflammatory
myopathies (see below). In terms of tissue fibrosis, M2a
macrophages are generally considered the most impor-
tant [12]. They express specific cell surface markers
such as the mannose receptor CD206 and the type II
IL-1 decoy receptor, in addition to releasing a range of
regulatory cytokines such as IL-10 and the soluble IL-1
receptor antagonist (IL-1Ra) as well as many pro-fibrotic
molecules such as transforming growth factor (TGF)-b,
fibronectin, proline, several types of tissue inhibitor of
matrix metalloproteinases (TIMP) and chemokine (C-C
motif) ligand (CCL)17. CCL17 in particular has been
shown to enhance fibrosis in several mouse models of
pulmonary disease by binding to CC chemokine recep-
tor (CCR)4 [30]. An additional reason for the ability of
M2 macrophages to neutralize the M1 pro-inflammatory
response is their high level of expression of arginase
(ARG)1, which directly competes with M1-associated
inducible nitric oxide synthase (iNOS) for L-arginine
[31] (see below and Figure 4C).
Several groups have used different in vitro and in vivo
animal models in attempts to unravel the role of macro-
phages in myogenesis, muscle repair, fibrosis, and the
development and treatment of DMD. In vitro,p r o -
inflammatory macrophages have a positive influence on
myoblast proliferation while repressing myoblast
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Page 6 of 20Figure 4 Inflammatory and fibrotic traits in dystrophic muscle of patients with DMD and mdx mice. (A) Fibrin(ogen) accumulates in
muscles of patients with DMD and in aged mdx mice. Immunohistochemistry for fibrin(ogen) (brown) in muscle biopsies of (top) patients with
DMD and healthy subjects and in (bottom) wild-type (WT) and mdx diaphragms. (B) Increased fibrosis, fibroblast number and TGFb signaling in
dystrophic muscles. Staining for collagen deposition (Sirius red) and immunohistochemistry for fibroblast-specific protein (FSP)-1 and P-Smad2
was performed on muscle biopsies taken from patients with DMD and healthy subjects. (C) Presence of alternatively activated macrophages in
diaphragm muscle of mdx mice. Cells double-positive for CD206 (red) and Arginase I (green) in mdx diaphragm are shown by
immunofluorescence with specific antibodies. The relative increase in the number of these cells in the mdx diaphragm over time is shown. Bars
=5 0μm.
Mann et al. Skeletal Muscle 2011, 1:21
http://www.skeletalmusclejournal.com/content/1/1/21
Page 7 of 20differentiation, whereas anti-inflammatory macrophages
stimulate both myoblast differentiation and fusion.
Importantly, in vivo depletion of blood monocytes, from
which M1 and M2 macrophages probably arise, was
shown to have negative effects on the muscle-repair
process after injury [23]. Conversely, BM transplantation
experiments have revealed an important role for the CC
chemokine receptor 2/monocyte chemotactic protein-1
(CCR2/MCP-1) ligand, and for the proteolytic activity of
urokinase plasminogen activator (uPA)/plasmin in skele-
tal-muscle repair by regulating the recruitment of BM-
derived macrophages into injured muscle [32-37].
Several studies of macrophage depletion or impaired
macrophage recruitment have revealed crucial functions
of macrophages in the regulation of fibrogenesis in dys-
trophic muscle, and the potential for therapeutic inter-
vention [19,35,37,38]. Similar benefits on the dystrophic
phenotype in mdx mice were reported after using a vari-
ety of anti-inflammatory agents acting on cytokines such
as TNFa and on their cellular receptors, or on other
major pro-inflammatory mediators such as nuclear fac-
tor (NF)-B [39-41]. Additionally, the presence of alter-
natively activated M2a macrophages was shown to
increase progressively with age in the diaphragms of
fibrotic mdx mice [27] (Figure 4C). Similarly, fibrinogen
depletion in mdx mice diminished fibrosis, concomitant
with a significant decrease in the number of M2a
macrophages in the diaphragm. In patients with DMD,
fibrosis has also been associated with increased numbers
of alternatively activated macrophages [42]. Overall,
these studies show that appropriate modulation of
macrophage activity might ameliorate the progression of
dystrophy.
A potentially important link between arginine metabo-
lism by M2a macrophages and abnormal repair or fibro-
sis development has recently been shown by several
groups. In one study, deletion of two c-AMP response
element (CREB)-binding sites from the C/EBP-b promo-
ter specifically impaired M2 but not M1 gene expres-
sion, interfering with the later stages of injury-induced
m u s c l er e g e n e r a t i o n .M u t a n tm i c ew e r ea b l et or e m o v e
necrotic tissue from injured muscle, but they exhibited
severe defects in myofiber regeneration [43]. Mutation
of the C/EBP-b promoter also reduced ARG1 expression
in macrophages, which was hypothesized to reroute
arginine metabolism away from arginase-mediated poly-
amine synthesis toward iNOS-mediated NO production,
which was previously shown to promote the degradation
of the key myogenic transcription factor MyoD [44].
Indeed, similar shifts in macrophage polarization and
macrophage competition for arginine metabolism were
seen to influence the severity of the muscle pathology in
mdx dystrophic mice [28]. In another study [14], Th2
cytokines increased the expression and activity of
arginase by M2 macrophages in mdx mice, with intri-
guing differences in the effects of arginase-2 deletion in
different muscles. Indeed, although fibrosis is reduced in
quadriceps and diaphragm of mdx mice lacking argi-
nase-2, it seems that it is not the case for the soleus, the
cardiac muscle and the longissimus dorsi. More impor-
tantly from the clinical perspective, long-term dietary
supplementation with arginine increased skeletal and
cardiac muscle fibrosis in dystrophic mice, in contrast
to the reported benefits from short-term supplementa-
tion, thus suggesting caution is needed regarding dietary
arginine supplementation for patients with DMD [45].
Taken together, these studies indicate the crucial roles
of macrophage polarization in both muscle repair and
fibrogenesis, particularly in dystrophic muscle.
Aberrant repair and fibrosis in IIMs
In addition to the muscular dystrophies, there is another
group of chronic muscle disorders, collectively known as
myositis or the IIMs [46]. Phenotypically, IIMs are char-
acterized by muscle weakness, poor endurance, and
ongoing regeneration of the muscle tissue. Within the
muscle, the presence of inflammatory infiltrates com-
posed largely of macrophages, T cells and dendritic cells
correlates with immune-mediated loss of muscle fibers
and an inability to resolve the regeneration process
effectively. Although not fully characterized, an impor-
tant feature of these diseases is the persistence of pro-
inflammatory M1 macrophages and associated cytokines
such as IL-1, IL-15 and TNFa in the tissue, and an
apparent inability to switch to anti-inflammatory M2
macrophages. Hence, the most effective treatments to
date have proven to be glucocorticoids and other non-
steroidal anti-inflammatory agents (NSAIDs) such as
ibuprofen and aspirin. However, one problem with these
drugs has been their ability to promote fiber atrophy
[47], in addition to their negative effect on prostaglandin
(PG) synthesis via interference with cyclooxygenase
(COX) gene functions. PGs have been shown to play
various roles in many stages of myogenesis, and are
secreted from regenerating muscle [48,49]. Interestingly,
macrophage-derived TGFb1 has been shown to induce
PGE2 expression from myoblasts via a COX-2-depen-
dent mechanism, which in turn diminishes TGFb1
expression, forming an important feedback loop that
can control inflammation and fibrosis development [49].
One other limitation of the drugs used to treat IIMs is
that they do not produce complete recovery, nor do
they address the underlying defects, which in most cases
are multifactorial and not fully defined [50]. Nonethe-
less, the IIMs represent an important group of diseases
to help us understand the complicated role of pro-
inflammatory cells and cytokines in orchestrating nor-
mal versus aberrant muscle repair.
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fibrosis
Macrophages are not the only cells in the immune sys-
tem known to play a role in muscle repair and dystro-
phy. Tissue repair and fibrosis is also tightly regulated
by the Th cell response. Like macrophages, T lympho-
cytes can differentiate into different functional types,
which are named Th1 and Th2 cells, and which orches-
trate the host response by generating distinct cytokine
profiles [26]. CD4+ Th1 cells produce cytokines that
promote cell-mediated immunity, including IFN-g,
TNFa, IL-12 and IL-2, all of which have been found to
be anti-fibrotic cytokines. By contrast, CD4+ Th2 cells
promote humoral immunity, and produce the pro-fibro-
tic cytokines IL-4, IL-5, IL-6 and IL-13. Th1 cytokines
inhibit the development of Th2 cells, and conversely,
Th2 cytokines inhibit the development of Th1 cells.
Clearly, alterations or imbalances in these pathways
have the potential to skew repair towards anti- or pro-
fibrotic pathways, as witnessed by the importance of
Th2 cytokines in the development of liver fibrogenesis
[12]. T-cell-produced cytokines also regulate muscle
degeneration and repair. For example, loss of uPA pro-
teolytic activity in transgenic knockout mice reduces
macrophage and T-lymphocyte infiltration of injured
muscle, in association with more persistent myofiber
degeneration [33]. Moreover, scid/mdx mice, which are
deficient in functional T and B lymphocytes, develop
much less diaphragm fibrosis at 1 year of age, concomi-
tant with a decrease in activated TGFb in skeletal mus-
cle, compared with normal mdx mice [51]. In nu/nu/
mdx mice, (immunodeficient nude mice in the mdx
background) the lack of functional T cells alone was
associated with less diaphragm fibrosis at 3 months,
supporting the pathogenic role for T cells in mdx mus-
cle, and revealing this lymphocyte subclass to be an
important source of TGFb1 [52].
A specific subpopulation of T cells expressing the
Vb8.1/8.2 T-cell receptor (TCR) was recently identified
and shown to be enriched in mdx muscle. These T cells
produce high levels of osteopontin, a cytokine that pro-
motes immune-cell migration and survival [53], and
osteopontin levels are increased in patients with DMD
and in mdx mice after disease onset. Importantly, loss of
osteopontin in mdx double-mutant mice diminishes the
infiltration of natural killer T-cell (NKT)-like cells, which
express both T and NK cell markers and neutrophils, in
addition to reducing the levels of TGFb. These results
correlated well with improvements in muscle strength
and reduced diaphragmatic and cardiac fibrosis [53]. Not
all studies have produced such definitive results, and the
implication of lymphocytes and their subtypes in muscle
repair and fibrosis clearly requires further study. For
example, thymectomy at 1 month of age induces near-
complete post-natal depletion of circulating T cells in
mdx mice and. when followed by anti-CD4 and/or anti-
CD8 antibody treatment, failed to improve diaphragm
fibrosis at 6 months of age in mdx mice [51,54,55]. In
another study, M2 macrophages were shown to influence
CD4+ Th cells, because ARG1-expressing macrophages
suppressed Th2 cytokine-driven inflammation and fibro-
sis in the liver induced by Schistosoma mansoni infection
[26]. Because these data demonstrate the complexity of
the mechanisms regulating inflammation and fibrosis
development, further studies are clearly necessary to
determine whether distinct types of Th responses and
macrophage subtypes operate in dystrophic muscle. and
how they mediate their interactions.
Fibroblasts, the collagen-producing cells in skeletal
muscle
When tissue is damaged, fibroblasts migrate into the
wound and begin to produce and remodel the ECM in
response to pro-fibrotic cytokines such as TGFb.S t r o -
mal fibroblasts produce cytokines, growth factors and
proteases that trigger and uphold acute and chronic
inflammatory/pro-fibrotic conditions. Indeed, although
the fibroblast is necessary and fundamental to tissue
homeostasis and normal wound repair, it is also a cru-
cial intermediate in chronic fibrotic diseases, in which
persistent inflammation is widely accepted to provoke
dysregulated fibroblast activity. Notably, one limitation
that has hindered studies of fibrotic disease has been the
lack of good genetic markers to label fibroblasts. It is
well established that in non-muscle systems. activated
fibroblasts may be identified by their increased prolifera-
tion, migratory ability, enhanced contractility. and
increased expression of vimentin and, in particular, a-
smooth-muscle actin (aSMA), a contractile protein of
stress fibers. These fibers are connected to the ECM
through specialized structures called ‘mature’ and
‘super-mature’ focal adhesions, and through intercellular
gap and adherent junctions. As a result, when aSMA
stress fibers contract, they exert mechanical tension on
the ECM, which in turn provides a mechanically resistant
support, hence the name ‘myofibroblast’. These cells are
associated with tissue repair and fibrosis in many tissues
and organs, including muscle, skin, liver, lung, bone and
cartilage [56]. However, despite their relevance in these
diseases, it remains unclear whether myofibroblasts really
do exist in fibrotic skeletal muscle, or whether they are
instead mature fibroblasts actively producing ECM com-
ponents. One reason for this controversy is that classic
markers such as vimentin or aSMA are also expressed by
myoblasts, albeit at lower levels than fibroblasts. How-
ever, a recent study has identified the transcription factor
Tcf4 as a potentially important marker of fibroblasts in
muscle, although follow-up studies are still needed to
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with the literature, we use the term ‘myofibroblast’ here
in the muscle context.
There are many possible origins of myofibroblasts.
Resident fibroblasts that differentiate in response to spe-
cific effectors are considered to be the main myofibro-
blast progenitor in most tissues. Alternatively,
myofibroblasts may arrive by the influx of circulating
BM-derived cells expressing CD34, CD45 and collagen I
(cells known as fibrocytes), which undergo further
reprogramming in the damaged area. Finally, it has been
shown in organs such as lung, kidney and liver that
there is a significant number of myofibroblasts derived
from parenchymal epithelial cells through the mechan-
ism of epithelial to mesenchymal transition (EMT).
Thus, transdifferentiation of distinct cell types into myo-
fibroblasts can potentially account for persistent ECM
deposition in chronically damaged tissues. Understand-
ing the origin of myofibroblasts is thus of great impor-
tance to develop new approaches to combat the fibrotic
process seen in diverse diseases.
Although fibroblasts are the major collagen-producing
cells, myofiber-associated satellite cells and C2C12 myo-
blasts have also been shown to express significant levels
of interstitial collagens I and III, which diminish during
the process of differentiation [58]. Whereas collagen I
can markedly suppress differentiation of C2C12 cells,
collagen III expression is retained in aged mdx myo-
genic cells. This suggests that conversion of myoblasts
into myofibroblasts with increasing age may occur via
positive feedback [58]. Collagen modifications, such as
non-enzymatically regulated crosslinking to produce
advanced glycation end (AGE) products, also increase
the stiffness of muscle connective tissue, thereby contri-
buting to impaired muscle function in the older person
[59]. Several recent studies in other models have also
investigated the induction of fibroblastic phenotypes in
myogenic cells. In one case, TGFb was able to induce
Smad-dependent upregulation of sphingosine kinase SK)
1 in C2C12 myoblasts, whereas pharmacological or
small interfering (si)RNA-mediated inhibition of SK1
prevented TGFb from inducing fibrotic markers. Rho/
Rho kinase signaling also appeared to be implicated in
the TGFb-mediated transition of myoblasts into myofi-
broblasts downstream of SK1 activation [60]. Similarly,
downregulation of Notch2 expression has also been
linked to non-muscle fibrotic tissue and TGFb-depen-
dent induction of myofibroblast markers in C2C12 myo-
blasts. Overexpression of active Notch2 in C2C12 cells
prevents TGFb from inducing the expression of aSMA
and collagen I, whereas more surprisingly, transient
knockdown of Notch2 by siRNA in cultured myoblasts
results in the differentiation of C2C12 myoblasts into
myofibroblastic cells that express fibrotic markers such
as aSMA and collagen I, even in the absence of TGFb.
Finally, Notch2 can inhibit the differentiation of myo-
blasts into myofibroblasts by directly counter-regulating
Notch3 and limiting its expression [61].
Fibrogenesis in aging muscle
The Notch pathway has also been strongly implicated in
aging-associated fibrosis. For example, analysis of the
microniche of aged murine muscle stem cells found
high levels of TGFb and its activated effector Smad3 in
both differentiated muscle fibers and satellite cells,
which was reciprocal to the levels of active Notch,
which is more abundant in the young microniche [62].
Increased levels of activated Smad3 levels in aged mus-
cles attenuate their regenerative capacity by binding to
the promoters and stimulating the expression of several
cyclin-dependent kinase (CDK) inhibitors (for example,,
p15, p16, p21 and p27), negative regulators of cell-cycle
progression. Importantly, this imbalance of TGFb/
pSmad3-Notch could be restored by forced activation of
Notch. Similar scenarios of reduced Notch activation
and increased TGFb/pSmad3 signaling have been
reported recently in aged human muscles [63].
In additional studies of aged muscle, the fate of muscle
stem-cell progeny was reported to be controlled by an
interaction between the Wnt and Notch pathways in
which glycogen synthase kinase (GSK)3b plays an impor-
tant role [64]. The mammalian ortholog of the Droso-
phila transcriptional coactivator Legless, BCL9/9-2, was
also shown in this study to be necessary for activation of
the canonical Wnt pathway in adult myogenic progeni-
tors, and for their Wnt-mediated commitment to differ-
entiation and effective muscle regeneration [64].
However, whether GSK3b and/or BCL9 mediate Wnt-
induced cell-fate changes from myogenic to fibrogenic
lineages in resting satellite cells awaits further validation.
An earlier study by the same group had already high-
lighted the role of the canonical Wnt pathway in age-
associated fibrosis, linking increased collagen deposition
in aged regenerating muscles to a greater percentage of
fibrogenic cells arising from the conversion of myogenic
into non-myogenic cells [65]. This fibrogenic conversion
could be abrogated experimentally by treating mice with
Wnt inhibitors. Wnt3A stimulation negatively modulated
cell proliferation in young regenerating muscles, aug-
menting fibrosis. Thus, aging was associated with altera-
tions in the systemic environment, and because these
effects were reversible, this work provides the strategic
basis for interventions aimed at improving tissue repair
and at reducing fibrosis in pathological conditions.
Fibrogenesis versus adipogenesis in muscle repair
It is known that when regeneration fails, the fibrotic
scar is infiltrated with adipocytes (fatty degeneration) in
Mann et al. Skeletal Muscle 2011, 1:21
http://www.skeletalmusclejournal.com/content/1/1/21
Page 10 of 20addition to fibroblasts [66]. However, the cellular origin
of fatty infiltration remains controversial. Two indepen-
dent contributions to this debate have recently been
published, which identified a novel type of resident mus-
cle cell that responds to damage in skeletal muscle,
termed the fibro/adipogenic progenitor (FAP) [67,68].
These cells express the mesenchymal marker platelet-
derived growth-factor receptor (PDGFR)-a and are not
myogenic either in vitro or in vivo, according to their
distinct embryonic origin. FAPs are thought to be a
source of pro-differentiation signals for myoblasts
during the process of muscle regeneration, and more
importantly, they show a strong tendency to generate
myofibroblasts and adipose cells [67,68]. Thus, although
FAPs display limited myogenic capacity both in vitro
and in vivo, the FAP population will persist in the tissue
if the regenerative process fails, and they will potentially
differentiate into adipocytes. This supports the view that
signals from the local environment help control FAP
fate, and may play a significant role in the successful
regeneration of healthy muscle (Figure 5). Whether FAP
conversion also occurs during aging, and whether
Basal lamina
ECM deposition
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Fibro/adipogenic
progenitor
Resident
macrophage
Fibroblast
Increased number 
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myogenic cells
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Atrophic myofiber er
Young
Old
Figure 5 Myofiber growth and extracellular matrix (ECM) accumulation after damage differ in young and aged muscles. (Top) In young
muscles in response to injury, the satellite cells under the basal lamina can be activated by environmental cues released by the neighboring cells
(a local milieu composed of fibroblasts, interstitial cells, resident macrophages, fibro/adipogenic progenitors (FAPs) and microvasculature-
associated cells) to eventually form new fibers almost indistinguishable to the pre-existing ones. (Bottom) In aged muscles, the repair process will
result in reduced size of newly formed myofibers and thickening of the basal lamina by enhanced deposition of ECM components, which could
potentially be ascribed to the increased presence and activity of resident fibroblasts (and/or FAPs), and to decreased satellite-cell myogenic
potential. Conversion of myogenic into fibrogenic cells could also contribute to ECM accumulation. These new microenvironment conditions
within the satellite-cell niche will impede efficient satellite-cell functions and muscle repair.
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this process, remain to be determined. Interestingly,
there is the suggestion that the type of injury in acute
models may drive the repair response towards more
fibrotic or more adipogenic repair, for example after gly-
cerol injury and acute ischemia, respectively [68,69],
although the mechanisms have not been extensively
investigated.
The role of TGFb in muscle repair and fibrosis
Most pro-fibrogenic polypeptides are produced by infil-
trating immune, inflammatory, mesenchymal and tissue-
specific cells, thereby facilitating paracrine pro-fibro-
genic effects that perpetuate inflammation-driven fibro-
sis (see below) (Figure 2, Figure 3) [12]. One of the
most potent pro-fibrogenic cytokines in vivo is TGFb.
Three TGFb isoforms have been described to date
(TGFb1, TGFb2a n dT G F b3), all of which are initially
generated as latent precursors [70]. When active TGFb
is liberated, it binds to a heterodimeric receptor com-
plex consisting of one TGFb type I receptor molecule,
termed activin-linked kinase (ALK)5, and one TGFb
type II receptor. In the canonical TGFb pathway in nor-
mal fibroblasts, ligand binding leads ALK5 to phosphor-
ylate Smad2 and 3, which in turn bind to Smad4 to
form a complex that is translocated to the nucleus,
which activates transcription [71]. However, TGFb has
also been shown to signal via several additional path-
ways, including p38 mitogen-activated protein kinase
(MAPK), which requires the heparin sulfate-containing
proteoglycan (HSPG) betaglycan; the Ras/MAPK kinase
(MEK)/extracellular signal-regulated kinase (ERK) path-
way, which requires the HSPG syndecan 4; the c-abl
pathway; and Jun kinase (JNK), which requires focal
adhesion kinase (FAK) and TGFb-activated kinase
(TAK)1 [72]. These signaling pathways seem to even-
tually modify gene expression in a promoter-selective
fashion. For example, FAK, JNK and TAK1 are required
for myofibroblast differentiation and a-SMA expression,
whereas ERK is required for collagen type I expression.
However, p38 MAPK does not seem to be involved in
the fibrogenic activity of TGFb. Thus, it is likely that
additional signaling pathways are abnormally activated
in muscle fibroblasts in a manner independent of the
canonical TGFb pathway.
TGFb is expressed in normal muscle after injury and
i nt h ed y s t r o p h i cm u s c l eo fp a t i e n t sw i t hD M Da n d
mdx mice [70], where it has the potential to induce
fibrosis around myofibers, probably by stimulating fibro-
blasts to produce ECM proteins such as collagen and
fibronectin. Equally important is the ability of TGFb to
decrease the production of enzymes that degrade the
ECM, such as collagenase, while increasing production
of proteins that inhibit ECM-degrading enzymes such as
TIMPs and plasminogen activator inhibitor (PAI)-1 (see
below). Direct injection of recombinant TGFb into ske-
letal muscle in vivo stimulates TGFb expression in myo-
genic cells in an autocrine fashion and induces
connective-tissue formation in the area of the injection
[73,74]. Moreover, myoblasts transfected with vectors
expressing TGFb can differentiate into myofibroblastic
cells after intramuscular transplantation, a process
inhibited by decorin, a small leucine-rich proteoglycan
that can bind to and inhibit TGFb (see also below)
[75,76]. Finally, latent TGFb-binding protein (LTBP)4
regulates the release and bioavailability of TGFb from
the ECM, where it has been shown to modulate fibrosis
in the context of muscular dystrophy in mice [77]
Taken together, these studies highlight the crucial role
of TGFb in the initiation of fibrotic processes, and in
the induction of differentiation of myogenic cells into
myofibroblastic cells in injured muscle.
TGFb also seems to play an important role in aging-
associated fibrosis and muscle impairment. Increased
TGFb levels have been reported during aging, possibly
activating SK1 signaling to trigger fibrosis [60]. Microar-
ray analyses of myogenic cells from aged animals also
revealed major alterations in the expression of many
genes dependent upon the activation of TGFb signaling
[78]. In particular, PAI-1, fibronectin and connective-tis-
s u eg r o w t hf a c t o r( C T G F ) ,w h i c ha r ea l lk n o w nt ob e
directly upregulated by TGFb, were upregulated in aged
myogenic cells, together with increased basal levels of
phosphorylated Smad2/3. Collectively, these data suggest
that TGFb signaling is constitutively active in aged myo-
genic progenitors, which may explain the increase in
fibrosis seen in aged muscles.
Antagonism of TGFb signaling by a number of thera-
peutic agents has been shown to inhibit fibrosis and
improve muscle regeneration in several experimental
and animal models. However, no agents have yet been
convincingly shown to reduce fibrosis once formed. For
example, direct immunomodulation of TGFb inhibited
connective-tissue accumulation and the progression of
fibrosis in the diaphragm of mdx mice, although inflam-
mation increased [79]. Reduced tissue fibrosis after
injury was also detected in mice treated with both dec-
orin- and angiotensin receptor antagonists, with decorin
also preventing TGFb-induced differentiation of myo-
genic cells into fibrotic cells [80]. Likewise, extended
treatment of mdx mice with losartan significantly
reduces diaphragmatic fibrosis with no apparent adverse
effects [81]. Similar results were reported in animals
treated with suramin, which acts by competing with
TGFb for receptor binding [82]. Finally, the administra-
tion of halofuginone to aged mdx mice improved car-
diac and respiratory function by drastically decreasing
the expression of collagen and significantly reducing
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none treatment was also shown to enhance myogenesis,
a feature that may be relevant to improve muscle regen-
eration and function in muscular dystrophy [84].
Other growth factors involved in fibrosis
development
CTGF
The effects of TGFb on fibrosis can at least be partially
mimicked and amplified by CTGF. Increased levels of
CTGF have been reported in skeletal muscle from
patients with DMD, dystrophic dogs and mdx mice
[85,86]. One of the most striking properties of CTGF is
its ability to induce collagen type 1, a5 integrin and
fibronectin in rat kidney fibroblasts, much more
potently than TGFb [87]. Subcutaneous injection of
TGFb can also regulate the production of CTGF in neo-
natal Swiss mice, while CTGF injection can cause a
fibrotic reaction equivalent to that of TGFb.T h i sf i b r o -
t i cr e s p o n s ei ss p e c i f i ct oT G F b and CTGF, and is not
mimicked by EGF, PDGF or FGF2 [87]. Although CTGF
seems to interact with decorin, which could be regulat-
ing its action, the exact role of CTGF in skeletal muscle
remains obscure. These results suggest a role for both
TGFb and CTGF in skeletal-muscle remodeling by
inducing fibrosis, inhibiting myogenesis and promoting
dedifferentiation of myoblasts into myofibroblast-like
cells [86].
Other growth factors involved in fibrosis
development
PDGF family
Another family of growth factors capable of inducing
fibroblastic changes in muscle is the PDGF family,
which includes PDGF-AA, PDGF-AB, PDGF-BB, PDGF-
CC and PDGF-DD. These molecules bind two different
PDGF receptors, a and b,a n da n din vivo they can
induce neutrophils, macrophages, fibroblasts and
smooth-muscle cells to migrate into a wound site and
proliferate. In vitro, PDGF production can be induced
by TGFb, which also stimulates fibroblasts to contract
collagen matrices and differentiate into myofibroblasts
[88]. In addition, PDGF can induce c-abl kinase activity,
similar to TGFb, in a non-canonical manner [89]. Thus,
it is not surprising that blocking c-abl activity has anti-
fibrotic effects. For example, the anti-neoplastic agent
imatinib selectively and competitively blocks the ATP
binding site of c-abl and several other tyrosine kinases,
including PDGF receptors and c-kit, and it diminishes
tissue fibrosis in many experimental mouse models of
fibrotic disorders [90]. PDGF and its receptors are also
upregulated in inflammatory cells and the regenerating
fibers of patients with DMD and mdx mice. Conse-
quently, administering imatinib to mdx mice reduced
fibrosis in the diaphragm, and attenuated skeletal-mus-
cle necrosis and inflammation, with concomitant
improvements in muscle function [91]. Complementary
studies showed that imatinib ameliorated dystrophy in
mdx mice after exercise, although treated mice also
exhibited significant weight loss [92].
Myostatin
Myostatin, also known as growth differentiation factor
(GDF)8, is a TGFb family member that is specifically
expressed in the skeletal-muscle lineage, where its most
characterized role is negative regulation of muscle
growth. Deficiency of myostatin increases skeletal mus-
cle mass, myofiber diameter and strength [93,94]. Nor-
mal myostatin signaling can be counter-regulated by the
extracellular protein follistatin [95]. However, myostatin
not only regulates the growth of muscle cells, but also
regulates muscle fibroblast activation and hence the pro-
gression of fibrosis [96]. Indeed, several groups have
reported improved regeneration and decreased fibrosis
in the absence of myostatin [74]. Similarly, mdx mice
lacking myostatin displayed less fibrosis in the dia-
phragm, and were also stronger and more muscular
than their normal mdx counterparts [97]. As a potential
therapeutic approach, immunological neutralization of
myostatin in mdx mice was shown to attenuate dystro-
phy by improving muscle regeneration and reducing
ECM accumulation [98]. The effects of myostatin may
reflect its direct stimulation of proliferation of muscle
fibroblasts, or their differentiation into myofibroblasts,
induced when myostatin binds to the activin receptor
IIB, as seen both in vitro and in vivo. In fibroblasts,
myostatin induces activation of the Smad, p38 MAPK
and AKT pathways to promote ECM synthesis [99]. Not
surprisingly, injection of recombinant myostatin protein
in vivo stimulates myofibers to express TGFb,w h i c h
can produce the autocrine pro-fibrotic effects described
above. Furthermore, TGFb induces myostatin produc-
tion, revealing a collaborative action of both pro-fibrotic
cytokines on muscle cells. An important consideration is
that the physiological role of myostatin in cardiac mus-
cle seems to differ significantly from its role in skeletal
muscle. Consequently, myostatin loss does not induce
cardiac hypertrophy nor does it modulate cardiac fibro-
sis in mdx mice [81].
Several other factors may also act by modulating
myostatin function. For example, the anti-fibrotic, pro-
regenerative effects of decorin may derive not only from
its ability to neutralize the effects of TGFb [73], but also
from its capacity to antagonize the action of myostatin
on both fibroblasts and myoblasts. Decorin is the main
proteoglycan present in the ECM of adult muscle. Bigly-
can is more weakly expressed, although both proteins
are augmented in mdx muscle [100,101]. Indeed,
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affect regenerative capacity, despite inducing delays in
new myofiber growth [100], decorin delivery to regener-
ating muscle via adenoassociated viral (AAV) vectors
prevents TGFb activation and fibrosis [76]. Decorin can
also upregulate the expression of the myostatin inhibitor
follistatin [74]. Overexpression of insulin-like growth
factor (IGF)-1 and the simultaneous loss of myostatin in
vivo have been found to have interesting synergistic
effects on myofiber growth and impaired fibrosis. Local
expression of a muscle-restricted IGF-1 transgene accel-
erates the regenerative process in injured skeletal mus-
cle, modulating the inflammatory response and limiting
fibrosis [39]. However, the mechanisms by which these
two genes combine to regulate fibrosis and muscle
regeneration are still uncleara n du n d e rs t u d y .O v e r a l l ,
myostatin has distinct fibrogenic properties that, when
considered in conjunction with other signaling systems,
suggests a co-regulatory relationship between TGFb,
CTGF, myostatin and decorin.
ECM remodeling in muscle repair
Fibrosis can develop as a consequence of dysregulated
wound-healing responses and/or excessive deposition of
ECM, preventing normal regeneration after tissue injury.
However, appropriate ECM deposition is crucial for effi-
cient repair because the ECM surrounding skeletal mus-
cle plays an important role in maintaining the structure
and reinforcing the contractile function of muscle.
Furthermore, the ECM sequesters and presents heparin-
binding growth factors to the fibers, such as hepatocyte
growth factor (HGF) and fibroblast growth factor (FGF),
and signals to the differentiated fibers through dystro-
glycan and sarcoglycan complexes [102,103]. Individual
components of the ECM have been analyzed in trans-
genic knockout models after muscle injury or pharma-
cological intervention, providing important insight into
the function of the ECM in normal conditions and dur-
ing muscle regeneration. In normal muscle, the external
lamina is composed of collagen IV, laminin, and
heparan sulfate proteoglycans, while the interstitial
matrix that surrounds the basal lamina contains col-
lagens I, III and V, fibronectin and perlecan [10,11,102].
The systematic and timely breakdown and replacement
of these layers is crucial to ensure complete and rapid
repair, while avoiding fibrosis.
Fibrin(ogen) in muscle repair and fibrosis
A key element of the provisional primary ECM in
injured skeletal muscle is fibrinogen and its end-product
fibrin, which are here collectively referred to as fibrin
(ogen). Excessive and persistent fibrin(ogen) deposition
is deleterious to myofiber repair. Transgenic mice that
have lost the fibrinolytic proteases uPA and plasmin
(see below) exhibit impaired muscle regeneration
because of defective fibrinolysis and also have accumula-
tion of fibrin after muscle injury [33,35]. Fibrin(ogen)
also accumulates in the muscles of human patients with
DMD and in the diaphragm of mdx mice (Figure 4A)
[27,37]. Importantly, fibrin(ogen) accumulation is also
correlated with increasing age and the progression of
fibrosis, whereas fibrin(ogen) depletion in mdx animals
can significantly rescue muscle fibrosis and disease
severity [27]. Fibrin(ogen) deposits may serve as impor-
tant triggers for the inflammatory responses, because of
their capacity to bind to the integrin receptor Mac-1 on
classically activated M1 macrophages [27] (see above).
For example, after the engagement of fibrin(ogen) with
Mac-1, macrophages in mdx muscle induce the expres-
sion of pro-inflammatory chemokines and cytokines that
can promote muscle degeneration, including IL-1b,
TNFa, IL-6 and MIP-2 [27]. Persistent fibrin(ogen)
deposition in dystrophic muscle sustains chronic inflam-
mation, characterized by the increasing presence of
alternatively activated macrophages in mdx muscle, as
dystrophy progresses with age [27]. As described above,
M2a macrophages have been shown to promote fibrosis
in several different pathogenic conditions [12], thus sup-
porting the notion that fibrin(ogen) may promote fibro-
sis by sustaining alternatively activated macrophages in
dystrophic muscle. Moreover, by binding to the aVb3
integrin receptor on fibroblasts, fibrin(ogen) can also
directly stimulate the expression of collagen [27]. These
findings emphasize the concept that fibrin(ogen) is not
merely a structural component of the transient matrix
formed after injury, but, rather it can further promote
tissue inflammation and fibrosis in persistent chronic
conditions, as in muscular dystrophy. Finally, the persis-
tence of components of the ECM produced immediately
after injury is clearly deleterious to muscle repair, at
least in part by promoting fibrosis.
The importance of matrix metalloproteinases in skeletal-
muscle repair
In addition to the direct synthesis of ECM components,
efficient muscle repair also requires factors that regulate
the proteolytic degradation of the ECM. These mole-
cules include a large family of matrix metalloproteinases
(MMPs), calcium-dependent enzymes that specifically
degrade collagens and non-collagenous substrates, and
their inhibitors, the TIMPs. Proteolysis is also modu-
lated by molecules of the plasminogen activation system
[[16,104]. Indeed, MMPs alone or in conjunction with
the plasminogen/plasmin system, can degrade ECM
components, which are essential for cell migration and
tissue remodeling.
The large family of MMPs includes various collage-
nases (MMP-1, MMP-8 and MMP-13), gelatinases
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MMP-10 and MMP-11), membrane-type metalloprotei-
nases (MMP-14, MMP-15, MMP-16, MMP-17, MMP-
24 and MMP-25), and the metalloelastase MMP-12 [16].
MMPs are released from damaged muscle and infiltrat-
ing cells in order to disrupt the basement membrane of
the fiber, thereby facilitating the recruitment of myo-
genic, inflammatory, vascular and fibroblastic cells to
damaged tissue. However, the function of MMPs is not
only controlled by their expression and release from
damaged muscle and inflammatory cells. Net MMP
activity also reflects the relative amount of activated
enzyme. Activation requires proteolytic cleavage of the
inactive precursor by either membrane-type (MT)1-
MMP [105] or plasmin, and cleavage of their corre-
sponding inhibitors [106]. For example, increased
TIMP-1 and TIMP-2 levels mediate a net decrease in
protease activity, and thus, matrix accumulation. The
serine protease plasmin can directly activate, at least in
vitro, a group of MMP pro-domains, such as proMMP-
1, proMMP-3, proMMP-9, proMMP-10 and proMMP-
11, while the activation of proMMP-2 also involves
hydrolysis by MT1-MMP during plasmin stimulation. In
some cases, active MMPs can also further activate the
proMMPs of other MMPs, thereby forming positive
feedback loops.
MMPs play an obvious role in the development of
fibrosis, because collagen accumulates when its rate of
synthesis is greater than the rate of breakdown by
MMPs/collagenases; that is, when the balance between
TIMP and MMP activity favors TIMPs. In addition to
their role in fibrosis, MMPs and serine proteases fulfill
many other roles in skeletal-muscle repair and satellite-
cell activity. For example, MT1-MMP is presumed to
help maintain myofiber integrity, as transgenic mice
deficient in MT1-MMP develop centrally nucleated
myofibers that are smaller than normal [105]. MMP-13
and MMP-1 also participate in ECM remodeling during
muscle repair [16,107,108], while gelatinase MMP-2
affects new fiber formation by promoting collagen IV
degradation in the basement membrane during myoblast
proliferation, migration and fusion. In addition, NO,
which is released by local and invading cells during
injury, can act as a pro-inflammatory molecule, and is
able to activate MMP-2, which in turn releases HGF.
Importantly, blockers of NOS function, such as nitro- L-
arginine methyl ester (L-NAME), have been shown to
decrease the acute inflammatory reaction and enhance
fibrosis in vivo, in part by decreasing iNOS, MMP-2 and
HGF [109,110].
Another gelatinase, MMP-9, has been attributed a key
role in satellite-cell activation during the initial phase of
muscle regeneration, in addition to its role in inflamma-
tion. Perhaps more importantly, the skeletal muscle of
adult mdx mice expresses high levels of latent and active
MMP-2 and MMP-9, and inhibiting MMP-9 activity was
shown to significantly improve regeneration and con-
tractile functions by reducing the structural deteriora-
tion of muscle, necrosis, inflammation and fibrosis
[16,111-113]. Similar results were achieved in aged mdx
mice after transplanting modified tendon fibroblasts
expressing MMP-9 and placenta growth factor (PlGF).
These cells restored a vascular network and diminished
collagen deposition, raising the exciting possibility of
using similar cell-based or gene therapies to improve
muscle function in patients with currently untreatable
advanced-stage dystrophies [114]. The protein ADAM12
(a disintegrin and metalloproteinase 12) has been shown
to produce benefits in the context of muscle dystrophy
and aging by upregulating utrophin and stabilizing the
plasma membrane [115]. However, chronically high
levels of ADAM12 inhibit satellite-cell responses and
delay myoblast differentiation, subsequently leading to
skeletal-muscle loss with accelerated fibrosis and adipo-
genesis in aged mdx mice.
The role of the plasminogen activation system in ECM
remodeling during repair of damaged muscle
The activity of MMPs can amplify or synergise in some
cases with proteases of the plasminogen activation sys-
tem in ECM remodeling during tissue repair, particu-
larly due to their capacity to degrade multiple ECM
proteins. The plasminogen activation system is centered
on an inactive, extracellular serine protease, plasmino-
gen, which is converted into the active enzyme, plasmin,
by two plasminogen activators (PAs): tissue-type plasmi-
nogen activator (tPA) and urokinase-type plasminogen
activator (uPA). Inhibition of the plasminogen activation
system occurs at the level of the PAs by PA inhibitor
(PAI)-1 or at the level of plasmin, by a2-antiplasmin
[104]. The main function of the plasminogen activation
system main function is to degrade fibrin [104], but it
also fulfills an important role in muscle ECM remodel-
ing by cleaving ECM-associated molecules, liberating
and/or activating latent forms of bioactive molecules
such as growth factors, angiogenic factors and cytokines
(particularly bFGF, TGFb, VEGF, HGF/SF and certain
MMPs). Many of these molecules may also help in the
activation of quiescent satellite cells and regulate subse-
quent myogenic programs.
It is not surprising that components of the plasmino-
gen activation system play important yet distinct roles
in muscle regeneration after injury. Whereas it has been
shown that both uPA and plasmin activity are necessary
for skeletal-muscle regeneration, tPA activity is dispen-
sable, indicating that no redundancy exists in muscle
[ 3 3 , 3 5 ] .B yc o n t r a s t ,t h en e g a t i v er o l eo fP A I - 1i nm u s -
cle regeneration is suggested by the improved muscle
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The plasminogen activation system also plays an impor-
tant role in muscular dystrophy. For example, increased
uPA expression was found in mdx muscle, whereas
genetic loss of uPA exacerbated dystrophy and impaired
muscle function in mdx mice [37]. Recent data also sug-
gest that PAI-1 may influence dystrophic muscle in
humans and mice, and that the uPA/PAI-1 balance
potentially affects muscle fibrosis (our unpublished
results). Satellite cells derived from human patients with
DMD produce more uPA receptor and PAI-1 and less
uPA than do normal satellite cells [116]. BM-derived
cells expressing uPA also seem to play a key role in
mdx muscle repair with transplantation experiments,
suggesting that it may act in a number of different ways.
Firstly, BM-derived uPA-expressing cells prevent exces-
sive deposition of fibrin through the normal role of
uPAs in fibrin degradation. Secondly, BM-derived uPA
also promotes myoblast migration, presumably by acti-
vating or increasing the availability of growth factors.
Finally, it increases infiltration of BM-derived inflamma-
tory cells, especially macrophages into damaged tissue.
However, genetic loss of the uPA receptor in mdx mice
failed to exacerbate muscular dystrophy, suggesting that
uPA exerts its proteolytic effects independently of its
receptor [37].
Based on all of the emerging data, it is tempting to
speculate that the pronounced fibrosis in seen in
patients with DMD is related to altered net proteolytic
activity in the dystrophic muscles, due to imbalances in
expression and activity of PA/MMP system components
[101,116]. In turn, this imbalance could provoke the
aberrant activation of latent TGFb, with serious conse-
quences for fibrosis. Although proteolytic processing by
plasmin and MMP is important, as are integrins and
thrombospondin, the full gamut of mechanisms leading
to TGFb activation is complex and remains poorly
understood.
Other factors affecting muscle ECM remodeling
Stem-cell antigen (Sca)-1 has been shown to influence
muscle regeneration by modulating ECM remodeling.
Sca-1-deficient mice exhibit defects in muscle regenera-
tion, as Sca-1 is a negative regulator of myoblast prolif-
eration and differentiation in vitro. These mice also
show enhanced fibrosis after injury, as a result of
reduced MMP activity. It is still not clear if Sca-1 acts
directly or indirectly to upregulate MMP activity, which
could in turn increase matrix breakdown and efficient
muscle regeneration, while halting fibrosis [117]. A
more recent follow-up study [118] related the increased
fibrosis of Sca-1-deficient mice to a reduced recruitment
of IgM and C3 to injured muscle, due to a specific
reduction in peritoneal IgM-producing B-1a cells.
Because Sca-1 also plays a role in the maintenance of
progenitor cells [119], it was hypothesized that the
reduction in B-1a cells was due to lineage-specific
defects in self-renewal. Regardless, recruitment of IgM
and C3 after muscle injury is essential for the recogni-
tion and clearance of dead cells by phagocytic macro-
phages and thus, efficient regeneration. Although more
detailed studies of the role of IgM and C3 in muscle
regeneration and fibrosis are necessary, C3 has already
been shown to influence the development of liver fibro-
sis in other animal models [120].
In aged mice, a Sca-1+, non-myogenic (MyoD-) and
non-immunohematopoietic (CD45-) cell population has
been proposed to favor fibrosis [121]. These cells are
found in aged regenerating muscle, or they can be clon-
ally derived from myoblasts isolated from aged animals
or late passage C2C12 cells, although they are uncom-
mon in young animals, in which they seem to retain a
greater myogenic potential and express MyoD. Impor-
tantly, these cells overexpress fibrosis-associated genes,
possibly in a manner regulated by Wnt2. Another recent
study identified an increase in a muscle-resident stromal
cell (mrSC) population in the muscles of mdx mice
[122]. Wnt3a was shown to promote the proliferation of
mrSCs in culture and the expression of collagen, while
exerting the opposite effects on cultured myoblasts.
Moreover, injecting Wnt3a into the tibialis anterior
muscles of adult wild-type mice significantly increased
the mrSC population and collagen deposition. Conver-
sely, injection of the Wnt antagonist DKK1 into the ske-
letal muscles of mdx mice significantly reduced fibrosis.
Thus, as described above, the canonical Wnt pathway
seems to augment the mrSCs population and to stimu-
late the production of collagen by these cells. Hence,
the Wnt pathway, and potentially mrSCs, are further
confirmed as targets for therapies to counteract fibrosis
during aging and in various myopathies.
Recent studies have implicated the IGF-family mem-
ber relaxin in the regulation of MMP expression and
fibrosis development. Treatment with relaxin was able
to limit fibrosis development after laceration in mice
[123]. Mechanistically, relaxin was shown to promote
myoblast proliferation and myogenesis in vitro by down-
regulating p21 and upregulating Pax7 expression, while
simultaneously increasing expression and activation of
several MMPs, an effect abrogated by the MMP blocker
GM6001 [123,124]. However, the mechanism of action
of relaxin in vivo is complicated by its combined effects
on myogenesis and fibrogenesis, and its apparent ability
to reduce inflammation and promote angiogenesis when
injected directly. Similar effects were also seen in aged
muscle [124]. Further studies are needed to identify the
key target cells of relaxin, the kinetics of its activity, and
whether its ability to limit collagen deposition applies to
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models of injury.
Muscle dysfunction and fibrosis in sarcopenia
In addition to the factors already described above, sev-
eral studies have highlighted additional characteristics of
aging skeletal muscle that influence regeneration and
fibrosis. For example, a major role for myofibers them-
selves in controlling the homeostasis of the ECM during
age-related sarcopenia has been proposed [125]. Indeed,
some of the muscular features associated with aging in
humans were reproduced prematurely in a mouse
model with the post-natal, muscle-specific deletion of
serum response factor (SRF), including type IIB myofi-
ber atrophy, sarcomere disorganization and endomysial
fibrosis. Impaired functional and morphological regen-
eration, in addition to persistent and increased fibrosis,
was also seen in this mouse model after cardiotoxin-
induced injury. Because in these mice SRF was selec-
tively ablated in post-mitotic myofibers, the impaired
regeneration and increased fibrosis was attributed to
secondary modifications of the stem-cell niche, coupled
with a modified environment that favored the appear-
ance and maintenance of fibrosis. Significantly, SRF pro-
tein expression is reduced with aging in mouse and
human muscle samples, suggesting a physiological role
for this factor in the pathogenesis of sarcopenia.
Studies of the effects of aging on the expression of
microRNAs in skeletal muscle of humans found that
several members of the Let-7 family were upregulated in
older subjects. Because Let-7 family members been
related to cell-cycle control, they may function to down-
regulate other genes involved in muscle-cell prolifera-
tion, which in turn might negatively affect the reduced
regenerative capacity of muscle seen with aging [126].
Aged human muscle also behaves differently from
young muscle after a similar modest level of damage,
with dysregulation of a particular set of transcripts
including transcripts related to fibrosis and connective-
tissue function [127]. The age-specific response to
damage seen in older people included higher protein
expression for NF-B, heat shock protein 70 and
STAT3 signaling. Increased STAT3-dependent
responses in aged versus young muscles have also been
reported in humans after resistance exercise, which has
being hypothesized to be related to the efficiency of
muscle repair and regeneration [128].
Conclusions
Fibrosis is the end result of a complex series of events that
follow tissue damage and inflammation. If this process is
faulty, excessive and persistent ECM deposition takes
place, and normal tissue is substituted by collagen scar,
resulting in tissue dysfunction. Dysregulated muscle repair
with persistent fibrosis rather than efficient regeneration
plays a prominent role in the clinical decline and reduced
life expectancy associated with severe muscular dystro-
phies, especially in DMD. If the fibrotic tissue could be
repaired and the dystrophic muscle be redirected towards
regeneration, at least to some extent, thereby preserving
muscle integrity, the health of such patients could be con-
siderably improved. Persistent fibrosis represents a major
obstacle for successful gene- and cell-based therapies for
DMD that aim to restore or replace the dystrophin gene.
Thus, modifications of the muscle environment aimed at
halting and/or reducing fibrosis in DMD are crucial to
attenuate disease progression, and to improve gene deliv-
ery and stem-cell grafts in otherwise untreatable patients.
Inflammatory cells, particularly macrophages, are crucial
in regulating tissue homeostasis and promoting aberrant
healing. They are emerging as indispensable players for
damage control and tissue remodeling on muscle injury,
and as principal mediators of pathological skeletal remo-
deling in diseases such as the IIMs and the dystrophies.
Despite their many functions, skeletal-muscle macro-
phages remain poorly characterized in molecular terms.
Evidence is evolving that muscle macrophages are a het-
erogeneous population, which probably derive from dis-
tinct origins in physiology and pathology. Finally, although
there have been many advances in deciphering the variety
of pathways involved in normal muscle regeneration and
muscular dystrophy-associated fibrosis, these have not yet
been translated into effective anti-fibrotic therapies for
patients with DMD. It seems likely that single-agent thera-
pies, such as growth-factor administration or antagonism
of a single signaling pathway, will have a very weak effect
on fibrosis at advanced disease stages in a clinical setting.
This is probably due to the redundancy of growth factors
and of the cellular participants, ECM components and sig-
naling pathways involved in muscle regeneration/fibrosis,
and to the rapid neutralization or elimination of individual
agents. Thus, combined strategies will be crucial to com-
bat fibrosis and ameliorate the progression of muscular
dystrophy, including systemic delivery of anti-fibrotic
agents and gene-corrected cells that could integrate envir-
onmental inputs from the host and convert them into bio-
logical transmitters.
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